SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2020
Commission File Number: 001-36815
Ascendis Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Tuborg Boulevard 12
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-228576, 333-203040, 333-210810, 333-211512, 333-213412, 333-214843 and 333-216883) and Form F-3 (Registration Numbers 333-209336, 333-211511, 333-216882, 333-223134 and 333-225284) of Ascendis Pharma A/S (the Company) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
On December 10, 2020, Michael Wolff Jensen informed the Board of Directors (the Board) of the Company that he will not stand for re-election to the Board at the Companys 2021 Annual General Meeting. Mr. Jensen will continue in his capacity as Senior Vice President, Chief Legal Officer of the Company and be registered as an officer of the Executive Board of the Company when his term on the Companys Board expires. Mr. Jensens decision and notice to the Board was not the result of any disagreement between Mr. Jensen and the Company, its management, the Board or any committee thereof, or with respect to any matter relating to the Companys operations, policies or practices.The Board intends to appoint current Board member, Albert Cha, M.D., Ph.D., to serve as Chair of the Board upon expiration of Mr. Jensens term as a member of the Board.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Ascendis Pharma A/S|
|Date: December 14, 2020||By:|
|Scott T. Smith|
|Senior Vice President and Chief Financial Officer|